

**AM09245PU-N****Monoclonal Antibody to BPH - Aff - Purified**

<b>Alternate names:</b>	Benign Prostatic Hyperplasia
<b>Quantity:</b>	0.5 mg
<b>Background:</b>	<p>Benign prostatic hyperplasia (BPH) is a disease of unknown etiology that significantly affects the quality of life in aging men. Histologic BPH may present itself either as symptomatic or asymptomatic in nature.</p> <p>Benign prostatic hyperplasia (BPH), also known as benign enlargement of the prostate (BEP), is a condition that characterized by an increase in prostate size due to the formation of large nodules in the periurethral region of the prostate. Common in middle-aged and elderly men, benign prostatic hyperplasia leads to an obstruction of the urethra, thus interfering with normal urine flow and causing an urgency to urinate, as well as a decrease in urine flow. In some instances, benign prostatic hyperplasia can lead to recurrent urinary tract infections, bladder stones and kidney failure. These more serious afflictions are a direct result of an increase in the bacterial count within the bladder, a common phenomenon when urine flow is compromised. While mild cases of benign prostatic hyperplasia can be treated by a simple decrease in fluid intake, moderate to severe cases generally require medical treatment in the form of oral drugs or prostate surgery.</p>
<b>Host / Isotype:</b>	Mouse / IgM
<b>Clone:</b>	YPBH-1
<b>Immunogen:</b>	Highly purified Benign Prostatic Hyperplasia (BPH).
<b>Format:</b>	<p><b>State:</b> Lyophilized purified Ig fraction.</p> <p><b>Purification:</b> Affinity Chromatography on Protein G.</p> <p><b>Buffer System:</b> 0.01M PBS, pH 7.2 without preservatives.</p> <p><b>Reconstitution:</b> Restore with Double distilled water to adjust the final concentration to 1.0 mg/ml.</p>
<b>Applications:</b>	<p>This Benign Prostatic Hyperplasia antibody is suitable for use in ELISA and Immunohistochemistry.</p> <p>It was nor reaction in non-prostate normal tissue, neither prostate malignant tissue positive. This anti-BPH antibody can react with some of well-moderately differential prostate normal tissue and very rarely react with poor differential prostate normal tissue.</p> <p>Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.</p>
<b>Specificity:</b>	Reactive with BPH or Human prostate epithelial cells. Does not react with a variety of Human normal tissues
<b>Species Reactivity:</b>	<b>Tested:</b> Human.
<b>Storage:</b>	Store the antibody at -20°C. After reconstitution, aliquot and store at -20°C. Shelf life: one year from despatch.

**General Readings:**

1. Jacobsen, S.J. 2007. Risk factors for benign prostatic hyperplasia. *Curr Urol Rep.* 8: 281-288.
2. Edwards, J.L. 2008. Diagnosis and management of benign prostatic hyperplasia. *Am. Fam. Physician.* 77: 1403-1410.
3. Hoke, G.P. and McWilliams, G.W. 2008. Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. *Am. J. Med.* 121: S3-10.
4. Emberton, M., Cornel, E.B., Bassi, P.F., Fourcade, R.O., Gómez, J.M. and Castro, R. 2008. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. *Int. J. Clin. Pract.* 62: 1076-1086.
5. Dedhia, R.C. and McVary, K.T. 2008. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J. Urol.* 179: 2119-2125.
6. Miano, R., De Nunzio, C., Asimakopoulos, A.D., Germani, S. and Tubaro, A. 2008. Treatment options for benign prostatic hyperplasia in older men. *Med. Sci. Monit.* 14: RA94-R102.
7. Isaacs, J.T. 2008. Prostate stem cells and benign prostatic hyperplasia. *Prostate* 68: 1025-1034.
8. Lepor, H., Lepor, N.E., Hill, L.A. and Trohman, R.G. 2008. The QT interval and selection of alpha-Blockers for benign prostatic hyperplasia. *Rev Urol.* 10: 85-91.
9. Rittmaster, R., Hahn, R.G., Ray, P., Shannon, J.B. and Wurzel, R. 2008. Effect of Dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. *Urology* 72: 808-812.